South Korea · Delayed Price · Currency is KRW Livsmed Statistics
Total Valuation
Livsmed has a market cap or net worth of KRW 862.65 billion. The enterprise value is 811.74 billion.
| Market Cap | 862.65B |
| Enterprise Value | 811.74B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Livsmed has 25.00 million shares outstanding. The number of shares has increased by 21.46% in one year.
| Current Share Class | 25.00M |
| Shares Outstanding | 25.00M |
| Shares Change (YoY) | +21.46% |
| Shares Change (QoQ) | +0.58% |
| Owned by Insiders (%) | 39.03% |
| Owned by Institutions (%) | 15.35% |
| Float | 13.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.33 |
| PB Ratio | 5.26 |
| P/TBV Ratio | 5.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.81, with a Debt / Equity ratio of 0.08.
| Current Ratio | 7.81 |
| Quick Ratio | 6.59 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.16 |
| Interest Coverage | -37.83 |
Financial Efficiency
Return on equity (ROE) is -24.04% and return on invested capital (ROIC) is -15.94%.
| Return on Equity (ROE) | -24.04% |
| Return on Assets (ROA) | -14.81% |
| Return on Invested Capital (ROIC) | -15.94% |
| Return on Capital Employed (ROCE) | -17.99% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.22 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 37,815.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 43.84 |
| Average Volume (20 Days) | 186,934 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Livsmed had revenue of KRW 52.82 billion and -26.54 billion in losses. Loss per share was -1,122.65.
| Revenue | 52.82B |
| Gross Profit | 26.47B |
| Operating Income | -31.11B |
| Pretax Income | -26.54B |
| Net Income | -26.54B |
| EBITDA | -27.37B |
| EBIT | -31.11B |
| Loss Per Share | -1,122.65 |
Balance Sheet
The company has 64.56 billion in cash and 13.65 billion in debt, with a net cash position of 50.91 billion or 2,035.97 per share.
| Cash & Cash Equivalents | 64.56B |
| Total Debt | 13.65B |
| Net Cash | 50.91B |
| Net Cash Per Share | 2,035.97 |
| Equity (Book Value) | 163.95B |
| Book Value Per Share | 6,555.92 |
| Working Capital | 102.15B |
Cash Flow
In the last 12 months, operating cash flow was -45.35 billion and capital expenditures -37.42 billion, giving a free cash flow of -82.77 billion.
| Operating Cash Flow | -45.35B |
| Capital Expenditures | -37.42B |
| Depreciation & Amortization | 3.74B |
| Net Borrowing | -852.98M |
| Free Cash Flow | -82.77B |
| FCF Per Share | -3,310.25 |
Margins
Gross margin is 50.11%, with operating and profit margins of -58.90% and -50.25%.
| Gross Margin | 50.11% |
| Operating Margin | -58.90% |
| Pretax Margin | -50.25% |
| Profit Margin | -50.25% |
| EBITDA Margin | -51.81% |
| EBIT Margin | -58.90% |
| FCF Margin | n/a |
Dividends & Yields
Livsmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.46% |
| Shareholder Yield | -21.46% |
| Earnings Yield | -3.08% |
| FCF Yield | -9.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Livsmed has an Altman Z-Score of 38.31 and a Piotroski F-Score of 1.
| Altman Z-Score | 38.31 |
| Piotroski F-Score | 1 |